首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery:A motion sickness medication
【24h】

Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery:A motion sickness medication

机译:盐酸异丙嗪的微胶囊凝胶剂,用于控制鼻腔给药:一种晕车药

获取原文
获取原文并翻译 | 示例
           

摘要

The current method of choice for astronauts to treat space motion sickness is an intra-muscular injection of promethazine hydrochloride (PMZ HCl) which is invasive and causes considerable local irritation and discomfort at the site of injection.Intra-nasal delivery is considered a feasible alternative route for administration of medications to treat space motion sickness.The purpose of this research is to develop a PMZ HCl formulation that can be administered intra-nasally without irritation (i.e.leukocyte infiltration) in the nasal epithelium when dosed at PMZ HCl concentrations greater than the cytotoxic limit.The biocompatibility of PMZ HCl was tested in vitro and was shown to be cytotoxic at concentrations greater than 10~(-5) molar regardless of pH.A controlled-release microencapsulated dosage formulation was developed using spinning disk atomization and release rates for the PMZ HCl microcapsules were determined in phosphate buffered saline.An animal study was conducted to determine the irritation response of rat nasal mucosa when dosed with encapsulated and non-encapsulated PMZ HCl.
机译:宇航员目前治疗空间晕动病的首选方法是肌内注射盐酸异丙嗪(PMZ HCl),这种方法具有侵入性,在注射部位会引起相当大的局部刺激和不适,鼻内给药被认为是可行的替代方法。本研究的目的是开发一种PMZ HCl制剂,当PMZ HCl的浓度大于25mg / ml时,可以鼻腔内鼻腔给药,而不会刺激鼻腔(白细胞浸润)。体外测试了PMZ HCl的生物相容性,并显示在大于10〜(-5)摩尔的浓度下均具有细胞毒性,无论pH值如何。在磷酸盐缓冲液中测定PMZ HCl微胶囊,并进行了动物研究以确定给予胶囊化和非胶囊化PMZ HCl时,对大鼠鼻粘膜有刺激性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号